People with a specific type of BRCA-mutated metastatic pancreatic cancer (“germline” BRCA mutation, meaning associated with an inherited BRCA gene change) who have received initial chemotherapy and whose disease has now stabilized or improved may be eligible to take part in POLO, a clinical study supported by AstraZeneca, to help scientists find better treatment options for people living with pancreatic cancer. This page provides further information about the POLO clinical trial.
A clinical study of olaparib in people who:
Are at least 18 years of age
- Have been clinically diagnosed with a type of pancreatic cancer known as adenocarcinoma that has spread outside of the pancreas (also known as metastatic pancreatic cancer)
- Have an inherited germline BRCA genetic mutation (gBRCA1 or gBRCA2)
- Have received one course (minimum of 16 weeks) of platinum-based chemotherapy, with the last dose completed 4–8 weeks before starting the study treatment (Platinum agents include carboplatin, cisplatin, and oxaliplatin)
- Have a tumor that has stabilized (not grown) or improved (shrunk / disappeared) during treatment with platinum-based chemotherapy
- Have reached a point in their chemotherapy where both they and their doctor believe having a pause or break in chemotherapy treatment is appropriate